TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: FL-2000 Study for Newly Diagnosed Follicular Lymphoma Patients With a High Tumor Burden
Brief Summary: The purpose of this study is to assess in a prospective multicentric study (Phase III) the introduction of a monoclonal antibody directed against B-cells associated with a standard therapy including chemotherapy and alpha-interferon in first line treatment of patients with a large tumor burden follicular lymphoma.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab, methylprednisolone, methotrexate, Drug: Methotrexate | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab, methylprednisolone, methotrexate, Drug: Methotrexate + Methylprednisolone | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab, methylprednisolone, methotrexate, Drug: Methotrexate + Infliximab | Intervention Type: DRUG; Name: Infliximab, methylprednisolone, methotrexate; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Methotrexate + Methylprednisolone; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Methotrexate + Infliximab; Assigned to Arm(s): C
B: Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): N/A
C: Arm Label: Abatacept + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Arm Label: Placebo + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Arm Label: Abatacept + Methotrexate Open Label; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label, Placebo + Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate
D: Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: FIRST BREATH: Neonatal Resuscitation in Developing Countries
Brief Summary: In developing countries, neonatal death from birth asphyxia is a major problem. This study will be conducted in several countries to determine if the combined Neonatal Resuscitation Program/Essential Newborn Care Program compared to the new World Health Organization (WHO) basic perinatal care education of health care providers (Essential Newborn Care Program) results in reduced mortality due to perinatal asphyxia.


Options:
A: Arm Label: NRP Training (Intervention); Type: EXPERIMENTAL; Interventions: Procedure: Neonatal Resuscitation | Arm Label: Control; Type: OTHER; Interventions: Procedure: Neonatal Resuscitation | Intervention Type: PROCEDURE; Name: Neonatal Resuscitation; Assigned to Arm(s): Control, NRP Training (Intervention)
B: Intervention Type: BEHAVIORAL; Name: Labor and Delivery Team Coordination Course; Assigned to Arm(s): N/A
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Low dose high frequency health worker training approach | Arm Label: Comparison; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Comparison | Intervention Type: BEHAVIORAL; Name: Low dose high frequency health worker training approach; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Active Comparison; Assigned to Arm(s): Comparison
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PRONTO training; Type: EXPERIMENTAL; Interventions: Other: PRONTO training | Intervention Type: OTHER; Name: PRONTO training; Assigned to Arm(s): PRONTO training

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: FIRST BREATH: Neonatal Resuscitation in Developing Countries
Brief Summary: In developing countries, neonatal death from birth asphyxia is a major problem. This study will be conducted in several countries to determine if the combined Neonatal Resuscitation Program/Essential Newborn Care Program compared to the new World Health Organization (WHO) basic perinatal care education of health care providers (Essential Newborn Care Program) results in reduced mortality due to perinatal asphyxia.


Options:
A: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: Neonatal resuscitation protocol | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard of care | Intervention Type: OTHER; Name: Neonatal resuscitation protocol; Assigned to Arm(s): intervention | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): control
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PRONTO training; Type: EXPERIMENTAL; Interventions: Other: PRONTO training | Intervention Type: OTHER; Name: PRONTO training; Assigned to Arm(s): PRONTO training
C: Arm Label: Facilities; Type: OTHER; Interventions: Other: HBB/ENC supplies | Arm Label: Master Trainers; Type: OTHER; Interventions: Behavioral: HBB/ENC Training and Equipment | Arm Label: Facilitators; Type: OTHER; Interventions: Behavioral: HBB/ENC Training and Equipment | Arm Label: Learners; Type: OTHER; Interventions: Behavioral: HBB/ENC Training and Equipment | Intervention Type: BEHAVIORAL; Name: HBB/ENC Training and Equipment; Assigned to Arm(s): Facilitators, Learners, Master Trainers | Intervention Type: OTHER; Name: HBB/ENC supplies; Assigned to Arm(s): Facilities
D: Arm Label: NRP Training (Intervention); Type: EXPERIMENTAL; Interventions: Procedure: Neonatal Resuscitation | Arm Label: Control; Type: OTHER; Interventions: Procedure: Neonatal Resuscitation | Intervention Type: PROCEDURE; Name: Neonatal Resuscitation; Assigned to Arm(s): Control, NRP Training (Intervention)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: FIRST BREATH: Neonatal Resuscitation in Developing Countries
Brief Summary: In developing countries, neonatal death from birth asphyxia is a major problem. This study will be conducted in several countries to determine if the combined Neonatal Resuscitation Program/Essential Newborn Care Program compared to the new World Health Organization (WHO) basic perinatal care education of health care providers (Essential Newborn Care Program) results in reduced mortality due to perinatal asphyxia.


Options:
A: Arm Label: Newhints; Type: EXPERIMENTAL; Interventions: Behavioral: Home visits | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Home visits; Assigned to Arm(s): Newhints
B: Arm Label: package; Type: EXPERIMENTAL; Interventions: Other: package of 3 interventions | Intervention Type: OTHER; Name: package of 3 interventions; Assigned to Arm(s): package
C: Arm Label: EmONC package; Type: EXPERIMENTAL; Interventions: Behavioral: EmONC package | Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: EmONC package; Assigned to Arm(s): EmONC package
D: Arm Label: NRP Training (Intervention); Type: EXPERIMENTAL; Interventions: Procedure: Neonatal Resuscitation | Arm Label: Control; Type: OTHER; Interventions: Procedure: Neonatal Resuscitation | Intervention Type: PROCEDURE; Name: Neonatal Resuscitation; Assigned to Arm(s): Control, NRP Training (Intervention)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Incentives Plus Bupropion for Smoking in Schizophrenics
Brief Summary: There is a high prevalence of smoking among people with schizophrenia, and there are few smoking treatment programs for these smokers. The aims of this study are to investigate the separate and combined effects of bupropion and a voucher incentive program on smoking in people with schizophrenia.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Contingency Management | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Non Contingent Control Condition | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Non Contingent Control Condition; Assigned to Arm(s): 2
B: Intervention Type: BEHAVIORAL; Name: Financial incentives; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bupropion | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Contingent reinforcement plus placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: non-contingent reinforcement plus bupropion | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Non-contingent reinforcement plus placebo | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Contingent reinforcement plus placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: non-contingent reinforcement plus bupropion; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Non-contingent reinforcement plus placebo; Assigned to Arm(s): 4
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Enhanced Traditional Care control; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced Traditional Care control | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Enhanced Traditional Care control; Assigned to Arm(s): Enhanced Traditional Care control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Tonsillectomy on Preventing Recurrent Streptococcal Throat Infections: A Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine whether tonsillectomy is effective in preventing further streptococcal pharyngitis episodes in patients with recurrent tonsillitis.


Options:
A: Arm Label: Adenotonsillectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Adenotonsillectomy | Arm Label: Adenotonsillotomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Adenotonsillotomy | Intervention Type: PROCEDURE; Name: Adenotonsillectomy; Assigned to Arm(s): Adenotonsillectomy | Intervention Type: PROCEDURE; Name: Adenotonsillotomy; Assigned to Arm(s): Adenotonsillotomy
B: Intervention Type: PROCEDURE; Name: (adeno)tonsillectomy; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: Other: no intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Tonsillectomy | Intervention Type: PROCEDURE; Name: Tonsillectomy; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: no intervention; Assigned to Arm(s): 1
D: Arm Label: Electrocautery tonsillectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Tonsillectomy, laser tonsillotomy, debrider tonsillotomy | Arm Label: Debrider tonsillotomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Tonsillectomy, laser tonsillotomy, debrider tonsillotomy | Arm Label: Laser tonsillotomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Tonsillectomy, laser tonsillotomy, debrider tonsillotomy | Intervention Type: PROCEDURE; Name: Tonsillectomy, laser tonsillotomy, debrider tonsillotomy; Assigned to Arm(s): Debrider tonsillotomy, Electrocautery tonsillectomy, Laser tonsillotomy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Exubera® (Inhaled Insulin) Compared With Subcutaneous Human Insulin Therapy in Adult Subjects With Type 2 Diabetes Mellitus: A Long-Term, Outpatient, Open-Label, Parallel-Group Comparative Trial
Brief Summary: This study is being done to find out the good and bad effects of inhaled insulin that is used by oral inhalation, to adult males and females with type 2 diabetes mellitus. The other name for this inhaled insulin is Exubera®.

This study included a 2-year comparative treatment period followed by a 6-month follow-up period during which inhaled insulin-treated subjects were switched back to subcutaneous short-acting insulin. After this follow-up period, all eligible subjects entered a comparative extension period that was to last for 5 years. When the comparative portion of the study was terminated, all subjects were requested to return for a final extension follow-up month 3 visit.


Options:
A: Arm Label: Low CHO; Type: EXPERIMENTAL; Interventions: Behavioral: Low CHO | Arm Label: High CHO; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High CHO diet | Intervention Type: BEHAVIORAL; Name: Low CHO; Assigned to Arm(s): Low CHO | Intervention Type: DIETARY_SUPPLEMENT; Name: High CHO diet; Assigned to Arm(s): High CHO
B: Arm Label: Inhaled Insulin; Type: EXPERIMENTAL; Interventions: Drug: Inhaled Insulin | Arm Label: Subcutaneous insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Subcutaneous insulin | Intervention Type: DRUG; Name: Inhaled Insulin; Assigned to Arm(s): Inhaled Insulin | Intervention Type: DRUG; Name: Subcutaneous insulin; Assigned to Arm(s): Subcutaneous insulin
C: Arm Label: Nutritional counseling & self blood glucose monitoring; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: nutritional counseling, Behavioral: self blood glucose monitoring | Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: nutritional counseling; Assigned to Arm(s): Nutritional counseling & self blood glucose monitoring | Intervention Type: BEHAVIORAL; Name: self blood glucose monitoring; Assigned to Arm(s): Nutritional counseling & self blood glucose monitoring
D: Arm Label: exercise; Type: EXPERIMENTAL; Interventions: Behavioral: specific training program | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: standard | Intervention Type: OTHER; Name: standard; Assigned to Arm(s): control | Intervention Type: BEHAVIORAL; Name: specific training program; Assigned to Arm(s): exercise

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.
Brief Summary: The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

To look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with heterozygous familial hypercholesterolemia


Options:
A: Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: torcetrapib/atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: torcetrapib/atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: torcetrapib/atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: It is widely believed that people who abuse alcohol can sustain a liver injury after taking doses of acetaminophen just above the recommended maximum dose. This study is designed to look at the interaction between acetaminophen, liver injury and alcohol abuse. Subjects will undergo baseline tests to ensure that they do not have liver damage at the time of enrollment. Each subject will be randomly assigned to receive either a therapeutic dose of acetaminophen or a placebo three times a day for four days. Subjects will have blood work drawn on a daily basis to monitor the status of the liver. These tests will include conventional markers of liver injury in addition to a novel biomarker of liver function, a-GST. Previous work in the investigators' group has shown that a-GST is a more sensitive indicator of liver injury following acetaminophen overdose (Sivilotti 1999, Sivilotti 2002 x 2). However, it has never been used to study the alcoholic population. The investigators believe that a-GST may detect a subclinical acetaminophen-induced liver injury that has previously gone unrecognized in the alcoholic population.


Options:
A: Arm Label: Ondansetron /acetylcysteine 20.25h; Type: OTHER; Interventions: Drug: Ondansetron, Drug: acetylcysteine | Arm Label: Placebo/acetylcysteine 20.25h; Type: OTHER; Interventions: Drug: acetylcysteine | Arm Label: Ondansetron/acetylcysteine 12h; Type: OTHER; Interventions: Drug: Ondansetron, Drug: acetylcysteine | Arm Label: Placebo/acetylcysteine 12h; Type: OTHER; Interventions: Drug: acetylcysteine | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): Ondansetron /acetylcysteine 20.25h, Ondansetron/acetylcysteine 12h | Intervention Type: DRUG; Name: acetylcysteine; Assigned to Arm(s): Ondansetron/acetylcysteine 12h, Placebo/acetylcysteine 12h | Intervention Type: DRUG; Name: acetylcysteine; Assigned to Arm(s): Ondansetron /acetylcysteine 20.25h, Placebo/acetylcysteine 20.25h
B: Intervention Type: DEVICE; Name: Molecular Adsorbent Recirculating System (MARS®); Assigned to Arm(s): N/A
C: N/A
D: Intervention Type: DRUG; Name: acetaminophen sustained-release; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-centre, Randomised, Placebo Controlled, Double Blind, Parallel Group Study in Female Patients to Evaluate Whether Tolterodine ER Can Reverse the Increased Bladder Wall Thickness in Patients With Overactive Bladder.
Brief Summary: The main aim of the study is to investigate whether taking Tolterodine for overactive bladder symptoms can reduce the thickness of the bladder wall, as measured by intra-vaginal ultrasound. This will help doctors to understand whether there is a link between changes in the thickness of the bladder wall and progression of symptoms.


Options:
A: Intervention Type: DRUG; Name: SPM 907; Assigned to Arm(s): N/A
B: Arm Label: 1: Solifenacin 5 mg + Mirabegron 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin succinate, Drug: Mirabegron, Drug: Placebo to match mirabegron | Arm Label: 2: Solifenacin 5 mg + Mirabegron 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin succinate, Drug: Mirabegron, Drug: Placebo to match mirabegron | Arm Label: 3: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match solifenacin succinate, Drug: Placebo to match mirabegron | Arm Label: 4: Solifenacin 5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin succinate, Drug: Placebo to match mirabegron | Arm Label: 5:Mirabegron 25 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirabegron, Drug: Placebo to match solifenacin succinate, Drug: Placebo to match mirabegron | Arm Label: 6: Mirabegron 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirabegron, Drug: Placebo to match solifenacin succinate, Drug: Placebo to match mirabegron | Intervention Type: DRUG; Name: Solifenacin succinate; Assigned to Arm(s): 1: Solifenacin 5 mg + Mirabegron 25 mg, 2: Solifenacin 5 mg + Mirabegron 50 mg, 4: Solifenacin 5 mg | Intervention Type: DRUG; Name: Mirabegron; Assigned to Arm(s): 1: Solifenacin 5 mg + Mirabegron 25 mg, 2: Solifenacin 5 mg + Mirabegron 50 mg, 5:Mirabegron 25 mg, 6: Mirabegron 50 mg | Intervention Type: DRUG; Name: Placebo to match solifenacin succinate; Assigned to Arm(s): 3: Placebo, 5:Mirabegron 25 mg, 6: Mirabegron 50 mg | Intervention Type: DRUG; Name: Placebo to match mirabegron; Assigned to Arm(s): 1: Solifenacin 5 mg + Mirabegron 25 mg, 2: Solifenacin 5 mg + Mirabegron 50 mg, 3: Placebo, 4: Solifenacin 5 mg, 5:Mirabegron 25 mg, 6: Mirabegron 50 mg
C: Intervention Type: DRUG; Name: Tolterodine ER; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
D: Arm Label: Behavioral Training; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral training | Arm Label: Drug Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxybutynin chloride, extended-release | Intervention Type: BEHAVIORAL; Name: Behavioral training; Assigned to Arm(s): Behavioral Training | Intervention Type: DRUG; Name: Oxybutynin chloride, extended-release; Assigned to Arm(s): Drug Therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Efficacy And Safety Study Of SU011248 Administered In A Continuous Daily Regimen In Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Brief Summary: To evaluate the anti-tumor activity of SU011248 (sunitinib) in cytokine-refractory metastatic renal cell carcinoma (RCC) when administered in a continuous treatment regimen


Options:
A: Intervention Type: DRUG; Name: Sutent; Assigned to Arm(s): N/A
B: Arm Label: SU011248 (sunitinib); Type: EXPERIMENTAL; Interventions: Drug: SU011248 (sunitinib) | Intervention Type: DRUG; Name: SU011248 (sunitinib); Assigned to Arm(s): SU011248 (sunitinib)
C: Arm Label: RAD001 +BSC; Type: EXPERIMENTAL; Interventions: Drug: RAD001 | Arm Label: Placebo (plus BSC); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: RAD001; Assigned to Arm(s): RAD001 +BSC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (plus BSC)
D: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1

Answer: B